<DOC>
	<DOC>NCT01505777</DOC>
	<brief_summary>The purpose of this study is to Evaluate the Optimal Dosage of Mosapride (Medirac) and Probitics in Irritable Bowel Syndrome Without Predominant Diarrhea.</brief_summary>
	<brief_title>Exploratory Clinical Study to Evaluate the Optimal Dosage of Mosapride and Probiotics in Irritable Bowel Syndrome Without Predominant Diarrhea</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Mosapride</mesh_term>
	<criteria>Aged 1875 years who satisfied RomeIII criteria for the diagnosis of IBS Signed informed consent IBSD evidence of cathartic colon or history laxative abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>irritable bowel syndrome without predominant diarrhea</keyword>
	<keyword>Probiotics(Medirac) 10/mosapride 10mg</keyword>
	<keyword>Probiotics(Medirac) 15/mosapride 10mg</keyword>
	<keyword>Probiotics(Medirac) 15/mosapride 15mg</keyword>
	<keyword>Probiotics(Medirac) 30/mosapride 15mg</keyword>
	<keyword>Probiotics(Medirac) placebo/mosapride placebo</keyword>
</DOC>